Viridian reports 2025 net loss of $342.6M; veligrotug PDUFA date June 30, 2026

Viridian Therapeutics, Inc.\DE

Cash, cash equivalents and marketable securities were $874.7M as of Dec 31, 2025, up from $717.6M.
Net loss for 2025 was $342.6M ($269.9M in 2024); R&D spend rose to $338.9M.
PDUFA target action date for veligrotug BLA is June 30, 2026; Priority Review ongoing.
MAA for veligrotug submitted to EMA in January 2026 for European approval.
Phase 3 REVEAL-1 topline data for elegrobart on track for Q1 2026; REVEAL-2 for Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.